Plasmacytoid dendritic cell-derived leukemia, commonly recognized within the spectrum of blastic plasmacytoid dendritic cell neoplasm (BPDCN), represents a rare yet highly aggressive hematologic malignancy characterized by distinctive immunophenotypic features and complex clinical behavior. Despite advances in hematopathology and molecular diagnostics, accurate identification remains challenging because of overlapping characteristics with acute myeloid leukemia and other hematological disorders. This research and review article investigates the pathological basis, diagnostic complexities, immunophenotypic characteristics, and clinical implications associated with leukemia arising from plasmacytoid dendritic cells. A comprehensive analysis of published literature was undertaken using only the selected foundational studies addressing classification systems, diagnostic criteria, clinical manifestations, pathological findings, and emerging therapeutic perspectives. The findings indicate that the disease exhibits unique expression patterns involving CD4, CD56, and CD123 while demonstrating substantial heterogeneity in clinical presentation. Early recognition and multidisciplinary diagnostic evaluation are essential for improving treatment selection and prognostic assessment. The study highlights persistent diagnostic ambiguities, evolving classification frameworks, and the necessity for standardized diagnostic pathways. The article contributes an integrated framework for understanding the biological and clinical dimensions of plasmacytoid dendritic cell-derived leukemia while identifying future directions for research and clinical management.